Open AccessMicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma
Author(s) -
Lei Shi,
Mengheng Wang,
Haiping Li,
You Peng
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s330881
Subject(s) - microrna , clear cell renal cell carcinoma , biomarker , renal cell carcinoma , medicine , diagnostic biomarker , clear cell , cancer , kidney cancer , biomarker discovery , cancer biomarkers , extracellular vesicles , liquid biopsy , cancer research , bioinformatics , oncology , biology , gene , proteomics , biochemistry , microbiology and biotechnology
Renal cell carcinoma (RCC) is the second most common cancer of the urinary system, accounting for approximately 10-15% of kidney cancers in the world. Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype with the highest mortality. Surgical resection or puncture of tumor tissue is still an important clinical treatment and diagnosis of ccRCC, but its high recurrence rate and poor prognosis often lead to the short survival period of patients. Hence, the development of novel molecular biomarkers is of great clinical importance. miRNAs are endogenous non-coding small RNAs with a length of 19-24 nt. A growing number of studies have reported that miRNAs, as proto-oncogenes or tumor suppressor genes, play a key role in the development of ccRCC and might be effective diagnostic and prognostic biomarkers. In addition, miRNAs can also predict the efficacy of treatment drug, thus improving the accuracy of clinical medication. Furthermore, non-invasive detection of miRNAs or extracellular vesicles (EV) in body fluids has better convenience and repeatability, which shows remarkable advantages compared with tissue detection. In this review, we summarized the typical miRNAs reported in recent years and place emphasis on evaluating miRNAs in different body fluids to provide reference for the clinical diagnosis and prognosis of ccRCC in the future.